- TV Footage
- Integrated Annual Reports
- Quarterly Statements
- Sustainability Report
- Newsletter Overview
- Social Media
- Media Contact
Monheim, May 29, 2020 – Bayer announced today the start of a series of Brussels-based dialogue events, inviting policy-makers and other key stakeholders to discuss new ways of making scientific information on pesticide risk assessments more transparent and easier to access. The first event is scheduled for Thursday, June 4, 2020 from 9:30 am to 10:45 am CET. EURACTIV, an independent media company focusing on EU policy and politics, will host a virtual conference where panel participants will discuss pesticide policies in the EU and the importance of transparency as they relate to the re-registration of glyphosate.
“We share the same values as the public when it comes to the safety of our families, our food and our environment. As the public interest in information on glyphosate and other pesticides continues to grow, we want to lead the way in providing better access to safety-related information and enhance the transparency of the regulatory process,” said Teresa Babuscio, Director of Agricultural Affairs, Crop Science Office Brussels. “We’ve made several commitments on transparency, sustainability and engagement. With this series of Bayer-supported events, we continue to listen and learn, illustrating our commitments.”
The upcoming EURACTIV event is the first in a series where Bayer facilitates the participation of scientists, journalists, policy makers and NGOs in the discussion around transparency in science and in particular around the re-registration process of glyphosate in Europe. The series of dialogue events follows the relaunch of the www.glyphosate.eu website, where the European Glyphosate Renewal Group (GRG) is disclosing all the information that is part of the re-registration of glyphosate on this new platform. This includes the pre-submission meeting minutes with the regulatory authorities as well as the December 2019 renewal application, with the full non-confidential part of the 2020 dossier scheduled to follow soon. With this, stakeholders will gain access to the regulatory information and can engage in the European re-registration process. Additional background information on the role of glyphosate in sustainable agriculture can be found on a dedicated glyphosate website owned by Bayer.
Transparency fosters public trust in science and regulatory processes
Noting that transparency is a catalyst for trust, Babuscio also pointed out that Bayer will continue to publicly disclose information about its agricultural innovation to reinforce the company’s commitment to continually raising the bar on transparency standards.
In December 2017, Bayer launched its transparency initiative, making its full, in-depth crop protection safety studies accessible via its dedicated web-based platform. To date, the company has made information available for 28 active substances, including all 107 Bayer-owned glyphosate safety study reports that were submitted as part of the last regulatory authorization process in the European Union.
Bayer will continue its path to enhanced transparency beyond glyphosate. Two new information modules on genetically modified (GM) seeds and plant breeding will provide new insights and explanations regarding the regulatory science process. Additionally, Bayer is opening its labs to show how rigorously its products and technologies are tested in order to ensure their safety, efficacy and sustainability.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
View Download Center